Regenxbio Inc (RGNX) Stock Price, Quote & News

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phas...

Industry: Biotechnology

Sector: Healthcare

Phone: 240 552 8181

Website: www.regenxbio.com

Address:

9804 Medical Center Drive, Rockville, United States

highnihilism Sep. 16 at 7:17 PM

IWM: Russell 2000 → $ORA Ormat Technologies $FLNG Flex Lng Ltd. $CCS Century Communities $RGNX Regenxbio $BJRI Bj's Restaurants

0 · Reply

squiggleburp Sep. 16 at 4:23 PM

$RGNX Ho ho ho! Squiggle Santa is bringing some 30 percent days for all of the children holding RGNX. We are still early for this party but like any party we need a crowd to make it work so let’s turn up the volume. Oh and don’t mind tiny TIM, we are using his crutches to prop the share price up, now hobble along little tiny Tim.

0 · Reply

highnihilism Sep. 16 at 3:04 PM

Biotech → $IDYA Ideaya Biosciences $RGNX Regenxbio $FOLD Amicus Therapeutics $RYTM Rhythm Pharmaceuticals $NRIX Nurix Therapeutics

0 · Reply

Haunting_Low Sep. 16 at 2:55 PM

$RGNX Staying in this until ~Feb, hopefully there is a nice run-up.

0 · Reply

squiggleburp Sep. 14 at 2:53 PM

$RGNX Hey squiggle happy Sunday. Looks like we are stuck in a $9-10 dollar range. We have tapped $10 multiple times. Sadly all unsubstantiated pops will be sold until an update drops. This is a great time to continue building a position.

0 · Reply

squiggleburp Sep. 12 at 8:34 PM

$RGNX You still here Squiggle? SB- Yup sure am. SB- added another chuck of shares. Sitting on my hands for now!

0 · Reply

squiggleburp Sep. 11 at 6:18 PM

$RGNX Scrabble anyone?

1 · Reply

squiggleburp Sep. 11 at 4:21 PM

$RGNX $FBIO RGNX Echo, echo echo! Anybody out there? Okay fux it, Here is a potential catalyst for this month. September 2025 press release about the RGX-121 BLA review extension, the company stated its plans to present updated pivotal trial data for RGX-121 at the International Congress of Inborn Errors of Metabolism (ICIEM) meeting in September 2025. Depending on the clarity and strength behind this statistical data we could see some volatility. I am not the only retail person trading and following this stock. Trust me, if there is a surprise or if the data is stronger than anticipated we will get an immediate bump! Speaking of bumps- BURP!

3 · Reply

squiggleburp Sep. 11 at 2:02 PM

$RGNX another day of lonely posting. No one took my invite? Ok. See you all at $18. Not if, when!

1 · Reply

squiggleburp Sep. 10 at 6:20 PM

$RGNX Well since I am the only one posting here as of the past several days let me prove to you all that other investors do exist! See below, so you know, Yah know? 👇

0 · Reply

Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome

Sep 8, 2025, 2:05 PM EDT - 8 days ago

REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 6, 2025, 8:29 AM EDT - 10 days ago

Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome

Sep 5, 2025, 7:05 AM EDT - 11 days ago

REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II

Aug 28, 2025, 7:05 AM EDT - 19 days ago

REGENXBIO to Participate in Upcoming Investor Conferences

Aug 19, 2025, 12:01 PM EDT - 4 weeks ago

FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year

Aug 18, 2025, 5:00 PM EDT - 4 weeks ago

REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II

Aug 8, 2025, 9:11 AM EDT - 5 weeks ago

REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 7:05 AM EDT - 5 weeks ago

REGENXBIO Reports Second Quarter 2025 Financial Results and Operational Highlights

Aug 7, 2025, 7:00 AM EDT - 5 weeks ago

REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy

Jul 31, 2025, 7:05 AM EDT - 6 weeks ago

REGENXBIO to Host Conference Call on August 7 to Discuss Second Quarter 2025 Financial Results and Operational Highlights

Jul 10, 2025, 11:54 AM EDT - 2 months ago

REGENXBIO Announces Publication of Preclinical Results Demonstrating Functional Benefits of Novel Microdystrophin Construct in RGX-202 Investigational Gene Therapy for Duchenne Muscular Dystrophy

Jun 6, 2025, 4:02 PM EDT - 3 months ago

Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome

Jun 5, 2025, 11:43 AM EDT - 3 months ago

Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer

Jun 5, 2025, 7:05 AM EDT - 3 months ago

REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Jun 2, 2025, 7:05 AM EDT - 3 months ago

REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202

May 19, 2025, 4:05 PM EDT - 4 months ago

REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million

May 14, 2025, 7:13 AM EDT - 4 months ago

FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment

May 13, 2025, 7:07 AM EDT - 4 months ago

REGENXBIO Inc. (RGNX) Q1 2025 Earnings Call Transcript

May 13, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO Announces FDA Acceptance and Priority Review of the BLA for RGX-121 for MPS II

May 12, 2025, 4:05 PM EDT - 4 months ago

REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights

May 8, 2025, 7:05 AM EDT - 4 months ago

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 28th Annual Meeting

Apr 30, 2025, 4:05 PM EDT - 4 months ago

REGENXBIO to Host Conference Call on May 12 to Discuss First Quarter 2025 Financial Results and Recent Operational Highlights

Mar 26, 2025, 12:31 PM EDT - 6 months ago

5 Reasons To Buy Regenxbio Right Now

Mar 19, 2025, 9:15 AM EDT - 6 months ago

REGENXBIO REPORTS POSITIVE BIOMARKER DATA FROM AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY

Mar 13, 2025, 6:44 PM EDT - 6 months ago

REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:05 PM EDT - 6 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates

Mar 10, 2025, 7:05 AM EDT - 6 months ago

REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 4, 2025, 7:31 AM EST - 7 months ago

REGENXBIO Announces Closing of Strategic Partnership with Nippon Shinyaku for MPS Diseases

Feb 26, 2025, 4:05 PM EST - 7 months ago

REGENXBIO to Host Conference Call on March 13 to Discuss Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Highlights

Feb 11, 2025, 3:20 PM EST - 7 months ago

Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns

Jan 30, 2025, 7:05 AM EST - 8 months ago

REGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025

Jan 16, 2025, 4:01 AM EST - 8 months ago

Regenxbio: Wet AMD ABBV-RGX-314 Results Remain On Track For 2026

AMD

Jan 15, 2025, 3:27 PM EST - 8 months ago

Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again

Jan 14, 2025, 5:00 AM EST - 8 months ago

REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases

Jan 13, 2025, 8:31 AM EST - 8 months ago

AbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical Program

ABBV

Dec 6, 2024, 6:29 PM EST - 10 months ago

Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

AMTM APO CMA CRI CRS HPP KELYA

Nov 18, 2024, 7:05 AM EST - 10 months ago

REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA

Nov 14, 2024, 7:05 AM EST - 10 months ago

REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202

Nov 6, 2024, 11:16 PM EST - 11 months ago

REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 11 months ago

REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates

Oct 31, 2024, 3:38 PM EDT - 11 months ago

REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track

Oct 30, 2024, 7:05 AM EDT - 11 months ago

REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights

Oct 21, 2024, 7:05 AM EDT - 11 months ago

REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024

Oct 18, 2024, 7:05 AM EDT - 11 months ago

REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting

Sep 23, 2024, 4:05 PM EDT - 1 year ago

REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference

Sep 17, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Appoints Mitchell Chan as Chief Financial Officer

Sep 3, 2024, 8:04 AM EDT - 1 year ago

REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term Systemic Effect

Aug 27, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO Announces Presentation at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Aug 8, 2024, 7:05 AM EDT - 1 year ago

REGENXBIO to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

highnihilism Sep. 16 at 7:17 PM

IWM: Russell 2000 → $ORA Ormat Technologies $FLNG Flex Lng Ltd. $CCS Century Communities $RGNX Regenxbio $BJRI Bj's Restaurants

0 · Reply

squiggleburp Sep. 16 at 4:23 PM

0 · Reply

highnihilism Sep. 16 at 3:04 PM

Biotech → $IDYA Ideaya Biosciences $RGNX Regenxbio $FOLD Amicus Therapeutics $RYTM Rhythm Pharmaceuticals $NRIX Nurix Therapeutics

0 · Reply

Haunting_Low Sep. 16 at 2:55 PM

$RGNX Staying in this until ~Feb, hopefully there is a nice run-up.

0 · Reply

squiggleburp Sep. 14 at 2:53 PM

0 · Reply

squiggleburp Sep. 12 at 8:34 PM

$RGNX You still here Squiggle? SB- Yup sure am. SB- added another chuck of shares. Sitting on my hands for now!

0 · Reply

squiggleburp Sep. 11 at 6:18 PM

$RGNX Scrabble anyone?

1 · Reply

squiggleburp Sep. 11 at 4:21 PM

3 · Reply

squiggleburp Sep. 11 at 2:02 PM

$RGNX another day of lonely posting. No one took my invite? Ok. See you all at $18. Not if, when!

1 · Reply

squiggleburp Sep. 10 at 6:20 PM

$RGNX Well since I am the only one posting here as of the past several days let me prove to you all that other investors do exist! See below, so you know, Yah know? 👇

0 · Reply

squiggleburp Sep. 10 at 6:15 PM

$RGNX $FBIO RGNX- If approved and we see partial adoption to RGX-121 what type of numbers can we anticipate? Well I’ll tell you Squiggle, For example, treating 160 patients in the first year as a base case could bring in about $240 million, ramping up to 500 to 600 patients by year three for annual revenue of $750 to 900 million. So considering we are already undervalued (490 million) what do you think happens to the share price Squiggleburp? SB- well, I think the share price doubles up like a heifer eating a haystack. SB- Well said Squiggleburp. I agree. $18.00 price target set by me TODAY! Did you hear that HC Wainwright? You called for $34.00 I bet we see $18.00 first. How do I know, because I am smaaaart! BURP!

1 · Reply

squiggleburp Sep. 10 at 5:58 PM

$RGNX So this happened today. Why wouldn’t there be a pullback!! These price targets should have sent us into orbit. I think Robert Burns is trying to mess with me. $52 price target from Chadan Capital? Wow, how much did that cost. TEE HEE! BURP! HC Wainwright has reaffirmed a “buy” rating on RGNX, setting a price target of $34.00, signaling a potential upside of roughly 250% from the current price. • Chardan Capital has also reiterated a “buy” rating and assigned a more ambitious price target of $52.00, pointing to a possible upside of approximately 435%. Wow, Squiggleburp great find.

0 · Reply

squiggleburp Sep. 10 at 5:26 PM

$RGNX $FBIO RGNX- Hey Squiggle is that you over there? SQUIGGLE reply’s “yeah it’s me, who else would It be? We are the only idiots in this chat room”! Squiggle responds “yeah I know squiggle, it’s just a matter of time before the hens start to roost”! Squiggle then says,” hey Squiggle, wasn’t it the same scenario as when we started pounding the table (amongst other things) insisting FBIO was heading up?” Squiggle fires back, “your learning squiggle, not long from now we will be sitting a pumpkin hair higher, so stop sniffing your pinky and hit the ask”!

0 · Reply

squiggleburp Sep. 10 at 4:02 PM

$FBIO $RGNX FBIO-Excellent rebound here. A run above $4 is almost a given. Sitting tight. I am excited for the days leading up to PDUFA- I will slowly scale out and leave a small position on. We may be above $8 by then- Gotta run, one of my pigs bit my neighbors wife. I can’t figure out how she got into the pen- BURP! RGNX- If you like FBIO for its steady run up you may love RGNX. Next stock to double in the coming months. Same theory, don’t be greedy and scale out before the FDA approval.

2 · Reply

squiggleburp Sep. 10 at 3:21 PM

$RGNX $FBIO $TNXP Okay so we tickled $10.08 intraday. Let the stock rock back and forth a bit. They showed their hand here. Someone is prepared to drag any unsubstantiated pops down on low volume. Assuming people are accumulating this jerking back and forth is a good thing. It’s an attempt to lock shares up. Being there is very little volume MMKRs remain in control. Just wait, we will have our day!

0 · Reply

squiggleburp Sep. 9 at 9:21 PM

$RGNX Excellent move. Keep it going!!! Soon this board will be buzzing. We are early to this party!

0 · Reply

squiggleburp Sep. 9 at 5:56 PM

$FBIO $IXHL $RGNX Eyes are back on FBIO suddenly. Spike in volume and I think we start heading up!

0 · Reply

squiggleburp Sep. 9 at 4:59 PM

$FBIO $IXHL $RGNX FBIO- OH BOY! Guess who’s back! I took advantage of the small pullback and dipped more than just my tip in it! This stock has so much more room to run and there is no doubt we get some incredible trading opportunities. People will be betting both sides of this trade. Which side are you on? My personal price target is $7-7.50. We should see that very soon! RGNX- another Bio play that I am more than certain will exhibit a strong upward trajectory! Both stock are heading North and are ready to explode!!!!! Burp!

1 · Reply

squiggleburp Sep. 9 at 4:10 PM

$ABVE $NUKK $ORBS $RGNX Very sure about this trade. It may take a few months but there is no doubt we get a speculative run up into February PDUFA. The previous delay may work to our advantage as it offered somewhat of a discounted entry. My personal price target is $13. I am slowly building a sizable position. BURP!

0 · Reply

squiggleburp Sep. 8 at 9:44 PM

$RGNX $ABVE $ORBS $NUKK RGNX- attention to all investors! Squiggleburp is just beginning to pound the table on yet another” multi bagger throat gagger $20 in your pie hole play. “ RGNX upcoming PDUFA. Price targets ranging from $24-40. Almost a unanimous buy rating on this stock. I have started to build a position and will continue to do so in the weeks/months prior to approval- Hop off your stench trenches and start gobbling up shares of what Stevie wonder was quoted saying” I can SEE the stock x 20 from here!” If that ain’t proof I don’t know what is- BUY- BYE-BURP!

1 · Reply

DarkOrb Sep. 8 at 5:32 PM

$RGNX Now guiding for first patient in DR phase 2b in "first half" of 2026 (from the MS conference today, link to webcast below). DMD enrollment expected to be complete next month. https://ir.regenxbio.com/events

0 · Reply

squiggleburp Sep. 8 at 3:40 PM

$RGNX Took a position. I will average down if I have to. FEBUARY PDUFA! Price target $24. Yes please!

1 · Reply

Market Cap	464.73M
Revenue (ttm)	83.33M
Net Income (ttm)	-227.10M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-272.53%
Debt to Equity Ratio	0.00

Volume	198,863
Avg Vol	601,148
Day's Range	N/A - N/A
Shares Out	50.51M
Stochastic %K	34%
Beta	1.17
Analysts	Strong Sell
Price Target	$30.17